# Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection

> **NCT03588923** · PHASE1 · COMPLETED · sponsor: **Nanjing Sanhome Pharmaceutical, Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** SH229
- **DRUG:** Placebos
- **DRUG:** SH229
- **DRUG:** Placebos
- **DRUG:** SH229
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03588923
- **Lead sponsor:** Nanjing Sanhome Pharmaceutical, Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-07
- **Primary completion:** 2018-08-10
- **Final completion:** 2018-08-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03588923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03588923, "Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03588923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*